Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy

Pharmacogenomics

Volumn 14, Issue 5, 2013, Pages 555-574

  Krens, Stefanie D ^a,b   McLeod, Howard L ^a   Hertz, Daniel L ^a  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

docetaxel; enzyme probe; paclitaxel; personalized medicine; pharmacogenetics; therapeutic drug monitoring

Indexed keywords

BETA TUBULIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROMYCIN; ESTRAMUSTINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROCORTISONE; MIDAZOLAM; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1 B3; PACLITAXEL; PHENAZONE; PREDNISONE; QUINIDINE; ROSIGLITAZONE; THALIDOMIDE; UNCLASSIFIED DRUG;

ABCB1 GENE; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BODY SURFACE; BREAST CANCER; BREATH ANALYSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; CYP2C8 GENE; CYP3A4 GENE; CYP3A5 GENE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG RESISTANCE; DRUG RESPONSE; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; ERYTHROMYCIN BREATH ANALYSIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENE; GENE IDENTIFICATION; GENOTYPE; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MOLECULAR PROBE; MUCOSA INFLAMMATION; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; STOMACH CANCER; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DRUG MONITORING; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PACLITAXEL; PHARMACOGENETICS; TAXOIDS;

EID: 84875938875     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.33     Document Type: Article

References (134)

1. Huizing MT, Misser VH, Pieters RC et al. Taxanes: a new class of antitumor agents. Cancer Invest. 13(4), 381-404 (1995
2. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4(4), 253-265 (2004 (Pubitemid 38525281)
3. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a Phase III trial. J. Clin. Oncol. 30(17), 2055-2062 (2012
4. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat. Rev. Drug Discov. 9(9), 677-678 (2010
5. Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M. Tesetaxel, a new oral taxane, in combination with capecitabine: a Phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 68(6), 1565-1573 (2011
6. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J. Clin. Oncol. 24(10), 1633-1642 (2006 (Pubitemid 46638788)
7. Pazdur R, Newman RA, Newman BM et al. Phase I trial of Taxotere: five-day schedule. J. Natl. Cancer Inst. 84(23), 1781-1788 (1992
8. Taxol® (paclitaxel) Injection Package Insert. Bristol-Myers Squibb, Princeton, NJ, USA (2011) .
9. Taxotere® (docetaxel) Injection Concentrate Package Insert. Sanofi-Aventis, Bridgewater, NJ, USA (2010
10. Steed H, Sawyer MB. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8(7), 803-815 (2007 (Pubitemid 47288979)
11. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel : recent developments. Clin. Pharmacokinet. 45(3), 235-252 (2006 (Pubitemid 43327491)
12. Monsarrat B, Mariel E, Cros S et al. Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab. Dispos. 18(6), 895-901 (1990
13. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J. Clin. Oncol. 5(8), 1232-1239 (1987 (Pubitemid 18045309)
14. Sparreboom A, Van Tellingen O, Scherrenburg EJ et al. Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab. Dispos. 24(6), 655-658 (1996 (Pubitemid 26000768)
15. van de Steeg E, van Esch A, Wagenaar E et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin. Cancer Res. 17(2), 294-301 (2011
16. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. 4(8), 815-818 (2005
17. Oshiro C, Marsh S, McLeod H, Carrillo M, Klein T, Altman R. Taxane pathway. Pharmacogenet. Genomics 19(12), 979-983 (2009
18. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8(5), 391-401 (1998 (Pubitemid 28475303)
19. Dai D, Zeldin DC, Blaisdell JA et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597-607 (2001 (Pubitemid 32953585)
20. van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int. J. Cancer 127(12), 2959-2964 (2010
21. Kwak JO, Lee SH, Lee GS et al. Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur. J. Pharmacol. 627(1-3), 92-98 (2010
22. Lagas JS, Vlaming ML, van Tellingen O et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin. Cancer Res. 12(20 Pt 1), 6125-6132 (2006 (Pubitemid 44703778)
23. Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic- pharmacodynamic relationships for docetaxel. Invest. New Drugs 19(2), 163-169 (2001 (Pubitemid 32423721)
24. Persohn E, Canta A, Schoepfer S et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur. J. Cancer 41(10), 1460-1466 (2005 (Pubitemid 40826471)
25. Bruno R, Olivares R, Berille J et al. Alpha-1- acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin. Cancer Res. 9(3), 1077-1082 (2003 (Pubitemid 36323714)
26. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov. 3(9), 739-748 (2004 (Pubitemid 39242826)
27. McLeod HL, Coulthard S, Thomas AE et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 105(3), 696-700 (1999 (Pubitemid 29277028)
28. Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004 (Pubitemid 41103619)
29. Bosch TM, Huitema AD, Doodeman VD et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin. Cancer Res. 12(19), 5786-5793 (2006 (Pubitemid 44629610)
30. Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin. Pharmacol. Ther. 79(6), 570-580 (2006 (Pubitemid 43833447)
31. Baker SD, Verweij J, Cusatis GA et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85(2), 155-163 (2009
32. Green H, Soderkvist P, Rosenberg P et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin. Pharmacol. Toxicol. 104(2), 130-137 (2009
33. Henningsson A, Marsh S, Loos WJ et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11(22), 8097-8104 (2005 (Pubitemid 41698753)
34. Bergmann TK, Brasch-Andersen C, Green H et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 11(2), 113-120 (2011
35. Fransson MN, Green H, Litton JE, Friberg LE. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab. Dispos. 39(2), 247-255 (2011
36. Marsh S, Somlo G, Li X et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7(5), 362-365 (2007 (Pubitemid 47484774)
37. Rodriguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 11(5), 621-623 (2010
38. Marsh S. Pharmacogenomics of taxane/platinum therapy in ovarian cancer. Int. J. Gynecol. Cancer 19(Suppl. 2), S30-S34 (2009
39. Tsai SM, Lin CY, Wu SH et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin. Chim. Acta 404(2), 160-165 (2009
40. Green H, Khan MS, Jakobsen-Falk I, Avall-Lundqvist E, Peterson C. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer. J. Pharm. Sci. 100(100), 4205-4209 (2011
41. Kim KP, Ahn JH, Kim SB et al. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother. Pharmacol. 69(5), 1221-1227 (2012
42. Leskelä S, Jara C, Leandro-García LJ et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 11(2), 121-129 (2011
43. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21), 3540-3546 (2009
44. Hertz DL, Motsinger-Reif AA, Drobish A et al. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res. Treat. 134(1), 401-410 (2012
45. Hertz DL, Roy S, Motsinger-Reif AA et al. CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann. Oncol. doi:10.1093/annonc/mdt018 (2013) (Epub ahead of print
46. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13(8), 481-494 (2003 (Pubitemid 37034590)
47. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007 (Pubitemid 46175758)
48. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 1794(5), 860-871 (2009
49. Sissung TM, Baum CE, Deeken J et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin. Cancer Res. 14(14), 4543-4549 (2008
50. Kim HS, Kim MK, Chung HH et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 113(2), 264-269 (2009
51. Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol. Rep. 23(1), 271-278 (2010
52. Bergmann TK, Brasch-Andersen C, Green H et al. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin. Pharmacol. Toxicol. 100(2), 199-204 (2011
53. Sissung TM, Mross K, Steinberg SM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 42(17), 2893-2896 (2006 (Pubitemid 44755257)
54. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78(1), 49-55 (2009
55. Chang H, Rha SY, Jeung HC et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol. 20(2), 272-277 (2009
56. Grau JJ, Caballero M, Campayo M et al. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel. Laryngoscope 119(8), 1484-1490 (2009
57. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 12(3 Pt 1), 854-859 (2006 (Pubitemid 43259868)
58. Johnatty SE, Beesley J, Paul J et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin. Cancer Res. 14(17), 5594-5601 (2008
59. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 99(5), 967-972 (2008 (Pubitemid 351997599)
60. Medeiros R, Pereira D, Afonso N et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int. J. Clin. Oncol. 8(3), 156-161 (2003 (Pubitemid 36897285)
61. Sun N, Sun X, Chen B et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 65(3), 437-446 (2010
62. Mir O, Alexandre J, Tran A et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann. Oncol. 20(4), 736-740 (2009
63. Murray GI, Taylor MC, McFadyen MC et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57(14), 3026-3031 (1997 (Pubitemid 27315056)
64. Shimada T, Watanabe J, Kawajiri K et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20(8), 1607-1613 (1999 (Pubitemid 29385452)
65. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 10(4), 343-353 (2000 (Pubitemid 30345182)
66. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 60(13), 3440-3444 (2000 (Pubitemid 30482162)
67. Bournique B, Lemarie A. Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos. 30(11), 1149-1152 (2002 (Pubitemid 35265818)
68. Sissung TM, Danesi R, Price DK et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 7(1), 19-26 (2008
69. Figg WD, Li H, Sissung T et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 99(5), 1047-1055 (2007 (Pubitemid 46587914)
70. Pastina I, Giovannetti E, Chioni A et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in castration-resistant prostate cancer (CRPC) patients. BMC Cancer 10, 511 (2010
71. Leandro-García LJ, Leskelä S, Jara C et al. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin. Cancer Res. 18(16), 4441-4448 (2012
72. Leandro-García LJ, Leskelä S, Inglada-Perez L et al. Hematological beta-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res. 72(18), 4744-4752 (2012
73. Monzo M, Rosell R, Sanchez JJ et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J. Clin. Oncol. 17(6), 1786-1793 (1999 (Pubitemid 29269248)
74. Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV. Beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res. 23(1B), 681-686 (2003 (Pubitemid 36358472)
75. Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 5(3), 158-164 (2004 (Pubitemid 38262847)
76. Sucheston LE, Zhao H, Yao S et al. Genetic predictors of taxane-induced neurotoxicity in a SWOG Phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res. Treat. 130(3), 993-1002 (2011
77. Baldwin RM, Owzar K, Zembutsu H et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin. Cancer Res. 18(18), 5099-5109 (2012
78. Deeken JF, Cormier T, Price DK et al. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform. Pharmacogenomics J. 10(3), 191-199 (2010
79. Hertz DL, McLeod HL, Irvin WJ Jr. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 17(5), 620-630 (2012
80. Frye RF. Probing the world of cytochrome P450 enzymes. Mol. Interv. 4(3), 157-162 (2004 (Pubitemid 38960844)
81. Liu YT, Hao HP, Liu CX, Wang GJ, Xie HG. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab. Rev. 39(4), 699-721 (2007
82. Fujita K. Cytochrome P450 and anticancer drugs. Curr. Drug Metab. 7(1), 23-37 (2006
83. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther. 48(2), 120-129 (1990 (Pubitemid 20263240)
84. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br. J. Clin. Pharmacol. 57(1), 44-53 (2004 (Pubitemid 38067949)
85. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6(4), 1255-1258 (2000 (Pubitemid 30226205)
86. Hurria A, Fleming MT, Baker SD et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin. Cancer Res. 12(20 Pt 1), 6100-6105 (2006 (Pubitemid 44703775)
87. Hooker AC, Ten Tije AJ, Carducci MA et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin. Pharmacol. Ther. 84(1), 111-118 (2008 (Pubitemid 351861492)
88. Michael M, Cullinane C, Hatzimihalis A et al. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)- erythromycin breath test and the antipyrine clearance test. Cancer Chemother. Pharmacol. 69(1), 125-135 (2012
89. Puisset F, Chatelut E, Dalenc F et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother. Pharmacol. 54(3), 265-272 (2004 (Pubitemid 39141744)
90. Puisset F, Chatelut E, Sparreboom A et al. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother. Pharmacol. 60(2), 305-308 (2007 (Pubitemid 46742545)
91. Goh BC, Lee SC, Wang LZ et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20(17), 3683-3690 (2002
92. Hilli J, Sailas L, Jyrkkio S, Pyrhonen S, Laine K. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother. Pharmacol. 67(6), 1353-1362 (2011
93. Zamboni WC, Combest AJ, DeLoia JA et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother. Pharmacol. 68(5), 1255-1262 (2011
94. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J. Clin. Oncol. 18(11), 2301-2308 (2000 (Pubitemid 30350223)
95. Yamamoto N, Tamura T, Murakami H et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J. Clin. Oncol. 23(6), 1061-1069 (2005 (Pubitemid 46202260)
96. Hertz DL, Walko CM, Bridges AS et al. Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure. Br. J. Clin. Pharmacol. 74(1), 197-200 (2012
97. Nishio M, Matsuda M, Ohyanagi F et al. Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy. Lung Cancer 49(2), 245-251 (2005 (Pubitemid 40966754)
98. Kurnik D, Wood AJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther. 80(3), 228-234 (2006 (Pubitemid 44301092)
99. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer 81(2), 330-335 (1999 (Pubitemid 29423714)
100. Connolly RM, Rudek MA, Garrett-Mayer E et al. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res. Treat. 127(1), 153-162 (2011
101. Kirchheiner J, Thomas S, Bauer S et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80(6), 657-667 (2006 (Pubitemid 44920222)
102. Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab. Dispos. 36(1), 73-80 (2008
103. Kinirons MT, O'Shea D, Kim RB et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin. Pharmacol. Ther. 66(3), 224-231 (1999 (Pubitemid 29451753)
104. Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin. Chem. 39(11 Pt 2), 2419-2430 (1993 (Pubitemid 23335135)
105. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam. Clin. Pharmacol. 16(4), 253-262 (2002 (Pubitemid 35205335)
106. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in Phase II studies in patients with cancer. J. Clin. Oncol. 16(1), 187-196 (1998 (Pubitemid 28041598)
107. Charles KA, Rivory LP, Stockler MR et al. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin. Pharmacokinet. 45(6), 611-622 (2006 (Pubitemid 44046487)
108. Ozawa K, Minami H, Sato H. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother. Pharmacol. 62(3), 551-557 (2008
109. Minami H, Kawada K, Sasaki Y et al. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients. Cancer Sci. 97(3), 235-241 (2006
110. Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J. Clin. Oncol. 23(3), 413-421 (2005 (Pubitemid 46224216)
111. Baker SD, Li J, ten Tije AJ et al. Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin. Pharmacol. Ther. 77(1), 43-53 (2005 (Pubitemid 40075388)
112. Engels FK, Loos WJ, van der Bol JM et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin. Cancer Res. 17(2), 353-362 (2011
113. Huizing MT, Keung AC, Rosing H et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J. Clin. Oncol. 11(11), 2127-2135 (1993 (Pubitemid 23332248)
114. Jiko M, Yano I, Sato E et al. Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers. Int. J. Clin. Oncol. 12(4), 284-290 (2007 (Pubitemid 47262740)
115. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13(1), 180-190 (1995
116. Joerger M, Huitema AD, Richel DJ et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin. Cancer Res. 13(21), 6410-6418 (2007 (Pubitemid 350075031)
117. Ohtsu T, Sasaki Y, Tamura T et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24- hour infusion. Clin. Cancer Res. 1(6), 599-606 (1995
118. Mould DR, Fleming GF, Darcy KM, Spriggs D. Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br. J. Clin. Pharmacol. 62(1), 56-70 (2006 (Pubitemid 44195243)
119. Mielke S, Sparreboom A, Steinberg SM et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. 11(13), 4843-4850 (2005 (Pubitemid 41557204)
120. Miller AA, Rosner GL, Egorin MJ, Hollis D, Lichtman SM, Ratain MJ. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin. Cancer Res. 10(24), 8325-8331 (2004 (Pubitemid 40053393)
121. Nakajima M, Fujiki Y, Kyo S et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J. Clin. Pharmacol. 45(6), 674-682 (2005 (Pubitemid 40696210)
122. Kobayashi M, Oba K, Sakamoto J et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan. Gastric Cancer 10(1), 52-57 (2007 (Pubitemid 46357474)
123. Huizing MT, Giaccone G, van Warmerdam LJ et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J. Clin. Oncol. 15(1), 317-329 (1997 (Pubitemid 27020590)
124. Woo MH, Relling MV, Sonnichsen DS et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin. Cancer Res. 5(3), 543-549 (1999 (Pubitemid 29131963)
125. de Jonge ME, van den Bongard HJ, Huitema AD et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin. Cancer Res. 10(7), 2237-2244 (2004 (Pubitemid 38445680)
126. Joerger M, Kraff S, Huitema AD et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin. Pharmacokinet. 51(9), 607-617 (2012
127. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 27(8), 1168-1176 (2009
128. Roychowdhury S, Iyer MK, Robinson DR et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3(111), 111ra121 (2011
129. Mielke S. Individualized pharmacotherapy with paclitaxel. Curr. Opin. Oncol. 19(6), 586-589 (2007 (Pubitemid 47508865)
130. Rizzo R, Spaggiari F, Indelli M et al. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res. Treat. 124(2), 593-598 (2010
131. Drugs @ FDA: FDA Approved Drug Products, Taxol (2012). www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails (Accessed 26 June 2012)
132. Drugs @ FDA: FDA Approved Drug Products, Taxol (2012). www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. DrugDetails (Accessed 26 June 2012) 202 Drugs @ FDA: FDA Approved Drug Products, Taxotere (2012). www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search. DrugDetails (Accessed 26 June 2012)
133. ClinicalTrials.gov: Taxanes search results. http://clinicaltrials.gov/ ct2/results?term=taxanes&pg=2%29 (Accessed 26 June 2012)
134. US FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers (2012). www.fda.gov/drugs/developmentapprovalprocess/ developmentresources/druginteractionslabeling/ucm093664.htm (Accessed 26 June 2012)